Treating TKI-induced Hypertension in Renal Cell Carcinoma

Share this content:
Inhibiting the VEGF signaling pathway can cause hypertension; there are, however, limited data on managing kinase inhibitor-induced hypertension.
Inhibiting the VEGF signaling pathway can cause hypertension; there are, however, limited data on managing kinase inhibitor-induced hypertension.

The American Cancer Society estimates that 62,700 new cases of kidney cancer will be diagnosed in the United States in 2016.Those with advanced disease may be treated with tyrosine kinase inhibitors (TKIs) that block vascular endothelial growth factor receptors (VEGFR); these agents include sorafenib, sunitinib, pazopanib, cabozantinib, axitinib, and lenvatinib. Although not a kinase inhibitor, bevacizumab also inhibits angiogenesis, and may be used in this treatment setting.

Inhibiting the VEGF signaling pathway can cause hypertension in patients treated with these agents. Although this adverse event is widely observed, there are limited data on managing kinase inhibitor-induced hypertension.2

In 2010, the Investigational Drug Steering Committee of the National Cancer Institute formed an interdisciplinary cardiovascular toxicities expert panel to make recommendations to the Cancer Therapy Evaluation Program on further study of this problem, and to formulate an approach for the management of TKI-induced hypertension by clinicians.

A key recommendation was that the target of blood pressure management should match the Seventh Joint National Committee (JNC 7) guidelines, with a goal blood pressure below 140/90 mmHg for patients without diabetes mellitus or kidney disease, and below 130/80 mmHg for patients with only 1 of these comorbidities.3

JNC 8 updates the committee's recommendations for the management of hypertension. For patients aged 60 years or older, antihypertensive drugs should be initiated when a patient's systolic blood pressure is 150 mmHg or greater, or when diastolic blood pressure is 90 mmHg or greater.4,5

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters